Vaxxas

1:45 PM - 2:00 PM, Wednesday, June 5, 2019 ・ Theater 3
Vaxxas is pioneering a next-generation vaccine delivery platform that enables robust immune system activation by targeting vaccine components to the abundant immunological cells immediately below the surface of the skin. Vaxxas' proprietary Nanopatch™ technology aims to provide an optimized, differentiated needle-free vaccine delivery solution that safely and cost effectively amplifies vaccine efficacy.
Ticker:
Not Provided.
Exchange:
Not Provided.
Company Type:
Company Website:
Company HQ State:
Not Provided.
Company HQ Country:
Australia
Year Founded:
2007
Main Therapeutic Focus:
Lead Product in Development:
Nanopatch
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.